Visual abstract | COMFORT-1 trial: Piclidenson for plaque psoriasis

The Psoriasis and Psoriatic Arthritis Hub is pleased to present a visual abstract summarizing results from the phase III, multicenter COMFORT-1 trial (NCT03168256) evaluating the safety and efficacy of piclidenoson (2 mg and 3 mg) compared with apremilast and placebo.¹ 

Piclidenoson, an A3 adenosine receptor agonist, down-regulates the NF-kB signaling pathway, inducing an anti-inflammatory effect.¹ A3 adenosine receptor agonists are highly expressed in the skin of patients with psoriasis, and previous phase II studies have demonstrated the clinical benefit of piclidenoson versus placebo. In this phase III study by Papp et al., piclidenoson was well tolerated up to 32 weeks.¹